Bouvardin is a Radiation Modulator with a Novel Mechanism of Action

Radiation Research

Volumn 184, Issue 4, 2015, Pages 392-403

  Stickel, Stefanie A ^a   Gomes, Nathan P ^a,c   Frederick, Barbara ^a   Raben, David ^a   Su, Tin Tin ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c SuviCa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOUVARDIN; CASPASE 3; CYCLIN D1; ELONGATION FACTOR 1ALPHA; ELONGATION FACTOR 2; HARRINGTONINE; HISTONE H3; PACLITAXEL; PROTEIN SYNTHESIS INHIBITOR; RADIOSENSITIZING AGENT; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; CYCLOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DISSOCIATION; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; EXPERIMENTAL RABBIT; FEMALE; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HEAD AND NECK CANCER; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IONIZING RADIATION; MITOSIS RATE; MOUSE; NONHUMAN; POLYSOME; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RADIATION DOSE; RADIATION EQUIPMENT; RADIATION EXPOSURE; RADIOSENSITIZATION; RIBOSOME; THERAPY EFFECT; TUMOR XENOGRAFT; WESTERN BLOTTING; X RAY GENERATOR; BRAIN TUMOR; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HELA CELLS; HUMANS; PEPTIDES, CYCLIC; PROTEIN BIOSYNTHESIS; RADIATION-SENSITIZING AGENTS;

EID: 84944789845     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR14068.1     Document Type: Article

References (49)

1. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 2013; 5.
2. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10:254-66.
3. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nature Genet 2002; 31:301-5.
4. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 1997; 57:5041-4.
5. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′cap. Nature 1990; 345:544-7.
6. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009; 11:903-8.
7. Joseph P, O'Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog 2004; 40:171-9.
8. Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012; 7:e41171.
9. DeFatta RJ, Nathan CO, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 2000; 110:928-33.
10. Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, et al. Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet 2014; 10:e1004105.
11. Braunstein S, Badura ML, Xi Q, Formenti SC, Schneider RJ. Regulation of protein synthesis by ionizing radiation. Mol Cell Biol 2009; 29:5645-56.
12. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005; 6:318-27.
13. Komar AA, Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 2011; 10:229-40.
14. Trivigno D, Bornes L, Huber SM, Rudner J. Regulation of protein translation initiation in response to ionizing radiation. Radiat Oncol 2013; 8:35.
15. Lu X, de la Pena L, Barker C, Camphausen K, Tofilon PJ. Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res 2006; 66:1052-61.
16. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and cmyc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005; 280:10964-73.
17. Kruiswijk F, Yuniati L, Magliozzi R, Low TY, Lim R, Bolder R, et al. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress. Sci Signal 2012; 5:ra40.
18. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
19. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25:6416-22.
20. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13:1886-918.
21. Moynihan MR, Pappenheimer AM, Jr. Kinetics of adenosinediphosphoribosylation of elongation factor 2 in cells exposed to diphtheria toxin. Infect Immun 1981; 32:575-82.
22. Gladstone M, Frederick B, Zheng D, Edwards A, Yoon P, Stickel S, et al. A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer. Dis Model Mech 2012; 5:342-50.
23. Sajithlal GB, Rothermund K, Zhang F, Dabbs DJ, Latimer JJ, Grant SG, et al. Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells 2010; 28:1008-18.
24. Merrick WC, Hensold JO. Analysis of eukaryotic translation in purified and semipurified systems. Curr Protoc Cell Biol 2001; Chapter 11:Unit 11.9.
25. Menzel DH. Fundamental formulas of physics. Mineola, NY: Dover Publications, Inc.; 1960.
26. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SAbetagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4:1798-806.
27. Tyagi A, Gu M, Takahata T, Frederick B, Agarwal C, Siriwardana S, et al. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17:5402-11.
28. Basrur VS, Chitnis MP, Menon RS. Radiometric evaluation of antibacterial activity of bouvardin (NSC 259968) on Escherichia coli and Staphylococcus aureus. Indian J Exp Biol 1986; 24:156-8.
29. Tobey RA, Orlicky DJ, Deaven LL, Rall LB, Kissane RJ. Effects of Bouvardin (NSC 259968), a cyclic hexapeptide from Bouvardia ternifolia, on the progression capacity of cultured Chinese hamster. Cancer Res 1978; 38:4415-21.
30. Zalacain M, Zaera E, Vazquez D, Jimenez A. The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett 1982; 148:95-7.
31. Arava Y, Wang Y, Storey JD, Liu CL, Brown PO, Herschlag D. Genome-wide analysis of mRNA translation profiles in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 2003; 100:3889-94.
32. Nolan RD, Grasmuk H, Drews J. The binding of tritiated elongation-factors 1 and 2 to ribosomes from Krebs II mouse ascites-tumore cells. The influence of various antibiotics and toxins. Eur J Biochem 1976; 64:69-75.
33. Yanamandra N, Kondraganti S, Srinivasula SM, Gujrati M, Olivero WC, Dinh DH, et al. Activation of caspase-9 with irradiation inhibits invasion and angiogenesis in SNB19 human glioma cells. Oncogene 2004; 23:2339-46.
34. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-22.
35. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-30.
36. Lawless C, Wang C, Jurk D, Merz A, Zglinicki T, Passos JF. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010; 45:772-8.
37. Essmann F, Engels IH, Totzke G, Schulze-Osthoff K, Janicke RU. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 2004; 64:7065-72.
38. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011; 474:230-4.
39. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11:957-72.
40. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9:297-308.
41. Giunta S, Belotserkovskaya R, Jackson SP. DNA damage signaling in response to double-strand breaks during mitosis. J Cell Biol 2010; 190:197-207.
42. Justice MC, Hsu MJ, Tse B, Ku T, Balkovec J, Schmatz D, et al. Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem 1998; 273:3148-51.
43. SirDeshpande BV, Toogood PL. Mechanism of protein synthesis inhibition by didemnin B in vitro. Biochemistry 1995; 34:9177-84.
44. Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, et al. The translation elongation factor eEF2 is a novel tumorassociated antigen overexpressed in various types of cancers. Int J Oncol 2014; 44:1461-9.
45. Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silfversvard C, et al. Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 1997; 73:678-83.
46. Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, et al. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol 2009; 34:1181-9.
47. Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, Tai S, et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010; 7:17-23.
48. Sun HG, Dong XJ, Lu T, Yang MF, Wang XM. Clinical value of eukaryotic elongation factor 2 (eEF2) in non-small cell lung cancer patients. Asian Pac J Cancer Prev 2013; 14:6533-5.
49. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010; 9:257-67.